e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

11.36 -0.38 (-3.24%)

Official Closing Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

BHVN Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Biohaven Pharmaceutical Holding Company Ltd. Is Fair to Shareholders

May 10, 2022

From Halper Sadeh LLP

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 10, 2022

Via Benzinga

Pfizer to Acquire Biohaven Pharmaceuticals

May 10, 2022

From Pfizer Inc.

Via Business Wire

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Where Biohaven Pharma Hldgs Stands With Analysts ↗

January 07, 2022

Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN...

Via Benzinga

European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine ↗

April 27, 2022

European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who...

Via Benzinga

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine

April 27, 2022

From Pfizer Inc.

Via Business Wire

Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle ↗

April 25, 2022

Last week, Axsome stock soared on its depression drug. This week is a different story.

Via Investor's Business Daily

AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship ↗

April 13, 2022

Flagship Pioneering is swiping one of AbbVie's biggest names.

Via Investor's Business Daily

Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

April 06, 2022

On Wednesday, Biohaven Pharma Holdings stock had its Relative Strength (RS) Rating upgraded to 92 from 86 a day ago.

Via Investor's Business Daily

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Biohaven Pharmaceutical's Return On Capital Employed Insights ↗

February 28, 2022

Biohaven Pharmaceutical (NYSE:BHVN) brought in sales totaling $190.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.81%, resulting...

Via Benzinga

Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals ↗

February 25, 2022

Biohaven inked a pair of deals that one analyst find promising for its pipeline.

Via Investor's Business Daily

Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals ↗

February 25, 2022

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY) to...

Via Benzinga

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗

February 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...

Via Benzinga

Biohaven Pharma: Q4 Earnings Insights ↗

February 25, 2022

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement....

Via Benzinga

Earnings Scheduled For February 25, 2022 ↗

February 25, 2022

Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •...

Via Benzinga

Biohaven Pharmaceutical's Earnings Outlook ↗

February 24, 2022

Biohaven Pharmaceutical (NYSE:BHVN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints ↗

February 14, 2022

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) reported topline results from an Asia-Pacific, Phase 3 trial of...

Via Benzinga

New Psychedelics ETF Launches On NYSE Arca ↗

February 02, 2022

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)...

Via Benzinga

This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut ↗

January 20, 2022

John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change.

Via Investor's Business Daily

2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)

January 06, 2022

Via AB Newswire

The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales ↗

January 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating...

Via Benzinga

Biohaven's Zavegepant Pain Spray Aces Late-Stage Migraine Trial ↗

December 06, 2021

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) is eyeing filing for approval in early 2022 for its experimental pain spray after new data showed it hit its...

Via Benzinga

What 6 Analyst Ratings Have To Say About Biohaven Pharma Hldgs ↗

November 10, 2021

Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ...

Via Benzinga

75 Biggest Movers From Yesterday ↗

November 10, 2021

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...

Via Benzinga

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M ↗

November 09, 2021

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S....

Via Benzinga

58 Stocks Moving In Monday's Mid-Day Session ↗

November 09, 2021

Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy